1. Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B.
- Author
-
Miesbach, Wolfgang, Meijer, Karina, Coppens, Michiel, Kampmann, Peter, Klamroth, Robert, Schutgens, Roger, Tangelder, Marco, Castaman, Giancarlo, Schwäble, Joachim, Bonig, Halvard, Seifried, Erhard, Cattaneo, Federica, Meyer, Christian, and Leebeek, Frank W. G.
- Subjects
- *
GENE therapy , *HEMOPHILIA , *PROMOTERS (Genetics) , *GENE expression , *HEMORRHAGE - Abstract
Gene therapy for hemophilia B aims to ameliorate bleeding risk and provide endogenous factor IX (FIX) activity/synthesis through a single treatment, eliminating the requirement for FIX concentrate. AMT-060 combines an adeno-associated virus-5 (AAV5) vector with a liver-specific promoter driving expression of a codon-optimized wild-type human FIX gene. This multinational, open-label study included 10 adults with hemophilia B (FIX ≤ 2% of normal) and severe-bleeding phenotype. No participants tested positive for AAV5-neutralizing antibodies using a green-fluorescent protein-based assay, and all 10 were enrolled. A single dose of 5 x 1012or 2 x 1013 genome copies of AMT-060/kilogram was administered to 5 participants each. In the low-dose cohort, mean endogenous FIX activity increased to 4.4 IU/dL. Annualized FIX use was reduced by 81%, and mean annualized spontaneous bleeding rate (ASBR) decreased from 9.8% to 4.6% (53%). In the higher-dose cohort, mean FIX activity increased to 6.9 IU/dL. Annualized FIX use decreased by 73%, and mean ASBR declined from 3.0 to 0.9 (70%). There was no reduction in traumatic bleeds. FIX activity was stable in both cohorts, and 8 of 9 participants receiving FIX at study entry stopped prophylaxis. Limited, asymptomatic, and transient alanine aminotransferase elevations in the low-dose (n 5 1) and higher-dose (n 5 2) cohorts were treated with prednisolone. No decrease in FIX activity or capsid-specific T-cell responses were detected during transaminase elevations. A single infusion of AMT-060 had a positive safety profile and resulted in stable and clinically important increases in FIX activity, a marked reduction in spontaneous bleeds and FIX concentrate use, without detectable cellular immune responses against capsids. This trial was registered at www.clinicaltrials.gov as #NCT02396342; EudraCT #2013-005579-42. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF